MTRAC Commissioning Support: Rifaximin (Targaxan®) for the prevention of recurrence of episodes of overt hepatic encephalopathy -

MTRAC Commissioning Support: Rifaximin (Targaxan®) for the prevention of recurrence of episodes of overt hepatic encephalopathy
Information type: Evidence summaries
Source: Midlands Therapeutics Review and Advisory Committee
Specialities: Liver disorders
Summary
MTRAC have reviewed rifaximin for the prevention of recurrence of episodes of overt hepatic encephalopathy and consider it to be suitable for prescribing in primary care, following initiation and stabilisation in secondary care and with the guidance of a shared-care agreement.
UKMi comment
MTRAC have published a template for effective shared care agreement for rifaximin alongside this commissioning support – this is available via the link below.
Related links: Effective shared care agreement template